IL109543A - Pharmaceutical compositions containing spiropiperidyl derivatives of rifamycin s for reducing severity of toxoplasmosis - Google Patents

Pharmaceutical compositions containing spiropiperidyl derivatives of rifamycin s for reducing severity of toxoplasmosis

Info

Publication number
IL109543A
IL109543A IL109543A IL10954394A IL109543A IL 109543 A IL109543 A IL 109543A IL 109543 A IL109543 A IL 109543A IL 10954394 A IL10954394 A IL 10954394A IL 109543 A IL109543 A IL 109543A
Authority
IL
Israel
Prior art keywords
rifabutin
spiropiperidyl
combination
rifamycin
infection
Prior art date
Application number
IL109543A
Other languages
English (en)
Other versions
IL109543A0 (en
Original Assignee
Palo Alto Medical Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/203,539 external-priority patent/US5529994A/en
Application filed by Palo Alto Medical Found filed Critical Palo Alto Medical Found
Publication of IL109543A0 publication Critical patent/IL109543A0/xx
Publication of IL109543A publication Critical patent/IL109543A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
IL109543A 1993-05-05 1994-05-04 Pharmaceutical compositions containing spiropiperidyl derivatives of rifamycin s for reducing severity of toxoplasmosis IL109543A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5728893A 1993-05-05 1993-05-05
US08/203,539 US5529994A (en) 1993-05-05 1994-02-28 Treatment for toxoplasmosis

Publications (2)

Publication Number Publication Date
IL109543A0 IL109543A0 (en) 1994-08-26
IL109543A true IL109543A (en) 1998-06-15

Family

ID=26736295

Family Applications (1)

Application Number Title Priority Date Filing Date
IL109543A IL109543A (en) 1993-05-05 1994-05-04 Pharmaceutical compositions containing spiropiperidyl derivatives of rifamycin s for reducing severity of toxoplasmosis

Country Status (14)

Country Link
US (5) US5670496A (ru)
EP (1) EP0648121B1 (ru)
JP (1) JPH07509003A (ru)
AT (1) ATE143601T1 (ru)
AU (1) AU669300B2 (ru)
CA (1) CA2138643A1 (ru)
DE (1) DE69400631T2 (ru)
DK (1) DK0648121T3 (ru)
ES (1) ES2095772T3 (ru)
GR (1) GR3021828T3 (ru)
IL (1) IL109543A (ru)
NO (1) NO950030L (ru)
RU (1) RU2121838C1 (ru)
WO (1) WO1994025038A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
EP1166117A2 (en) * 1999-03-19 2002-01-02 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6429231B1 (en) * 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US7074832B2 (en) 2001-09-24 2006-07-11 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US6858083B2 (en) * 2002-06-05 2005-02-22 Scimed Lifesystems, Inc. Apparatus and method for closed-loop control of RF generator for welding polymeric catheter components
US20030017985A1 (en) * 2002-07-02 2003-01-23 Taylor Gregory Alan Molecules that influence pathogen resistance
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
TW201434467A (zh) 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd 抗結核治療藥物及含彼之套組
US7799885B2 (en) * 2005-11-30 2010-09-21 Corning Incorporated Photo or electron beam curable compositions
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
SG10201405158QA (en) * 2006-02-24 2014-10-30 Callida Genomics Inc High throughput genome sequencing on dna arrays
FR2944014A1 (fr) 2009-04-06 2010-10-08 Univ Grenoble 1 Peptides cycliques a activite antiparasitaire
CN114601840A (zh) * 2020-12-08 2022-06-10 复旦大学附属中山医院 一种联合用药,用于治疗卡氏肺孢子虫肺炎
CN113230248A (zh) * 2021-06-18 2021-08-10 宁波大学 利卡灵-b及其组合物在制备治疗或预防弓形虫病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644616A (en) * 1969-03-24 1972-02-22 Ciba Geigy Corp Synergistic composition of rifampicin and streptomycin
US4054663A (en) * 1974-12-23 1977-10-18 Sankyo Company Limited Pyridine derivatives and their use as anticoccidial agents
US4094982A (en) * 1975-05-15 1978-06-13 Sankyo Company Limited Pyridine sulfonamides and their use as anticoccidial agents
IT1056272B (it) * 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
IT1135270B (it) * 1980-04-12 1986-08-20 Erba Farmitalia 3-amidino-ansamicine
US5175319A (en) * 1983-04-14 1992-12-29 Burroughs Wellcome Co. Naphthoquinone derivatives
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
DE3512194A1 (de) * 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
GB9000241D0 (en) * 1990-01-05 1990-03-07 Coopers Animal Health Pharmaceutical use
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis

Also Published As

Publication number Publication date
EP0648121A1 (en) 1995-04-19
US5641769A (en) 1997-06-24
DK0648121T3 (ru) 1997-02-24
RU2121838C1 (ru) 1998-11-20
AU6905094A (en) 1994-11-21
IL109543A0 (en) 1994-08-26
CA2138643A1 (en) 1994-11-10
WO1994025038A1 (en) 1994-11-10
RU95105973A (ru) 1997-01-20
NO950030D0 (no) 1995-01-04
EP0648121B1 (en) 1996-10-02
US5648345A (en) 1997-07-15
NO950030L (no) 1995-01-04
AU669300B2 (en) 1996-05-30
US5665707A (en) 1997-09-09
DE69400631T2 (de) 1997-02-27
US5650405A (en) 1997-07-22
DE69400631D1 (de) 1996-11-07
ES2095772T3 (es) 1997-02-16
US5670496A (en) 1997-09-23
ATE143601T1 (de) 1996-10-15
JPH07509003A (ja) 1995-10-05
GR3021828T3 (en) 1997-02-28

Similar Documents

Publication Publication Date Title
US5665707A (en) Treatment for toxoplasmosis with a composition comprising a lincosamide and a spiropiperidyl derivative of rifamycik S
JP6368294B2 (ja) マラリア、結核、及びｍａｃ病の治療方法
CZ288382B6 (en) Pharmaceutical preparation for treating viral infections
Araujo et al. Rifabutin is active in murine models of toxoplasmosis
Araujo et al. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection
US5529994A (en) Treatment for toxoplasmosis
Araujo et al. Recent advances in the search for new drugs for treatment of toxoplasmosis
Chang et al. Activity of minocycline against Toxoplasma gondii infection in mice
AU2009227092B2 (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
Chang et al. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii
AU775761B2 (en) Treatment or prevention of coccidiosis
Hinshaw et al. Present status of chemotherapy in tuberculosis
Hawryluk et al. Onchocerciasis drug discovery
Nelson et al. In vitro effectiveness of four cephalosporins against shigellae and clinical ineffectiveness of cephaloglycin
JPH09500646A (ja) アザスピランによるｈｉｖの治療法
Burns et al. Infections of the lower respiratory tract: treatment with amoxicillin
EP0711160A1 (en) Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes
EP0624089A1 (en) Methods
AU2008315718A1 (en) Idarubicin for the treatment of lymphoma in a dog
EP0552018A1 (en) Use of Rifabutin for delaying or preventing mycobacterial infections

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH Patent void